COMP <GO>
LMT vs TMO // ENTERPRISE SCALE & MARKET CAP
Lockheed Martin Corporation (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: LMT 8
— TMO 5
▲ ENTERPRISE SCALE & MARKET CAP LEADER: TMO
LAST: $643.59 (+2.20%) • MKT CAP: $148.67B
market-cap
$148.67B
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
market-cap
$262.22B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LMT VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LMT | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 10.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 26.40% | 9.30% | +17.10 | LMT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.6x | 30.4x | -14.80 | LMT | /valuation <GO> |
| Free Cash Flow Yield | 3.48% | 2.40% | +1.08 | LMT | /fcf-yield <GO> |
| Operating Margin | 10.30% | 17.40% | -7.10 | TMO | /operating-margins <GO> |
| Net Profit Margin | 6.70% | 15.10% | -8.40 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 5.60% | 3.90% | +1.70 | LMT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.11% | 0.24% | +1.87 | LMT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.73 | 4.50 | -0.77 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 76.7 | 62.9 | +13.80 | LMT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 0.94 | +0.17 | LMT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.5x | 36.3x | -8.80 | LMT | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $148.67B | $262.22B | -$113.55B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LMT REV | TMO REV | LMT GROSS % | TMO GROSS % | LMT FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $75.05B | $44.56B | 10.2% | — | $5.18B | $6.29B |
| FY 2024 | $71.04B | $42.88B | 9.8% | — | $3.78B | $7.27B |
| FY 2023 | $67.57B | $42.86B | — | — | $4.88B | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LMT // BETA 1.11
TMO // BETA 0.94